Targeting the Ras pathway in pediatric hematologic malignancies.

ABSTRACT:

Purpose of review

Ras pathway mutations are one of the most common type of alterations in pediatric hematologic malignancies and are frequently associated with adverse outcomes. Despite ongoing efforts to use targeted treatments, there remain no Food and Drug Administration (FDA)-approved medications specifically for children with Ras pathway-mutated leukemia. This review will summarize the role of Ras pathway mutations in pediatric leukemia, discuss the current state of Ras pathway inhibitors and highlight the most promising agents currently being evaluated in clinical trials.

Recent findings

Efficacy using RAF and MEK inhibitors has been demonstrated across multiple solid and brain tumors, and these are now considered standard-of-care for certain tumor types in adults and

SUBMITTER: Pikman Y 

PROVIDER: S-EPMC7880552 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature